GHRP-1
GHRP-1 is the first synthetic growth hormone releasing peptide discovered by Cyril Bowers, acting as a ghrelin receptor agonist with historical significance in the discovery of the GHS-R1a receptor and endogenous ghrelin.
Overview
GHRP-1 was among the first synthetic peptides demonstrated to stimulate growth hormone release independent of the GHRH pathway. Bowers and colleagues systematically modified enkephalin-derived peptides, discovering that certain hexapeptide configurations could potently release GH from pituitary somatotrophs through a then-unknown receptor. This work ultimately established an entirely new axis of GH regulation alongside GHRH and somatostatin. GHRP-1 is less commonly used in contemporary research compared to GHRP-2 and GHRP-6, which offer greater potency and better-characterized pharmacology.
Mechanism of Action
GHRP-1 binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily on pituitary somatotrophs. Receptor activation triggers intracellular calcium mobilization via the phospholipase C/inositol trisphosphate pathway, leading to GH vesicle exocytosis. GHRP-1 acts through a mechanism distinct from GHRH, which signals through the GHRH receptor via cAMP/protein kinase A. This independent mechanism allows GHRPs to synergize with GHRH for amplified GH release. GHRP-1 also demonstrated cardioprotective activity in fetal heart cell cultures, reducing apoptosis through mechanisms shared with other GHRPs (Muccioli et al., 2000).
Reconstitution Calculator
GHRP-1
GHRP-1 (Growth Hormone Releasing Peptide-1) is a synthetic hexapeptide and the f
Set up a clean workspace with all supplies ready.
7x / week for weeks
This calculator is provided for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment guidance. Always consult a qualified healthcare professional before preparing or administering any substance. PepGuide assumes no liability for decisions made based on these calculations.
Research
Growth Hormone Release
In comparative studies, GHRP-1 stimulates GH release from pituitary somatotrophs but with lower potency than GHRP-2 and GHRP-6. Bowers et al. demonstrated that structural modifications to the hexapeptide backbone could dramatically alter potency and selectivity, with GHRP-1 serving as the foundational scaffold from which more potent analogs were developed (Bowers et al., 1994). The peptide produces dose-dependent GH elevation with associated increases in cortisol and prolactin at higher doses.
Cardioprotection
Research in fetal heart cell cultures demonstrated that GHRP-1, along with GHRP-2 and GHRP-6, protects cardiomyocytes from apoptosis. This cardioprotective effect appears to be mediated through GHS-R1a signaling and is shared across the GHRP family, suggesting a conserved mechanism of cardiac cell survival independent of GH release (Muccioli et al., 2000).
Synergy with GHRH
Like other GHRPs, GHRP-1 demonstrates synergistic GH release when co-administered with GHRH or its analogs. Because GHRPs and GHRH activate distinct receptor pathways on somatotroph cells, the combined stimulus produces GH pulses 3-10 times greater than either agent alone. This synergy was first characterized using GHRP-1-class peptides and became a defining principle of growth hormone secretagogue pharmacology (Bowers, 1998).
Historical Discovery and GHS-R1a Identification
Cyril Bowers' systematic work with growth hormone releasing peptides throughout the 1980s and 1990s established the existence of a novel GH secretory pathway. GHRP-1 and its analogs demonstrated GH release that could not be explained by GHRH receptor activation, leading to the hypothesis and eventual cloning of the GHS-R1a receptor in 1996 by Howard et al. The subsequent identification of ghrelin as the endogenous GHS-R1a ligand in 1999 by Kojima et al. represented one of the most significant discoveries in endocrinology, connecting appetite, energy metabolism, and growth hormone regulation through a single receptor system (Bowers, 1998).
Safety Profile
GHRP-1 shares the general safety profile of growth hormone secretagogues. At standard research doses, it produces transient elevations in cortisol and prolactin that are dose-dependent and generally within physiological ranges. As with all GHS-R1a agonists, appetite stimulation and mild water retention may occur. GHRP-1 has been less extensively studied than GHRP-2 and GHRP-6, and comprehensive human safety data are limited. No serious adverse effects have been reported in published research at standard dosing.
Clinical Research Protocols
GHRP-1 has primarily been used in early investigational studies characterizing the GHS-R1a pathway rather than in formal clinical trials. Bowers and colleagues administered GHRP-1 intravenously at doses ranging from 0.1 to 1.0 mcg/kg in healthy volunteers, measuring serial GH, cortisol, and prolactin levels at 15-minute intervals for 60-90 minutes post-injection. These protocols established the dose-response characteristics and hormonal side-effect profile that guided development of subsequent GHRPs (Bowers et al., 1994). GHRP-1 was largely superseded by GHRP-2 for diagnostic applications due to the latter's greater potency and selectivity.
Synergies & Combinations
The primary documented synergy for GHRP-1 is with GHRH and its analogs. Co-administration produces synergistic rather than additive GH release, a property conserved across all GHRPs. In practice, GHRP-2 or ipamorelin have replaced GHRP-1 in combination protocols due to superior potency and selectivity. The GHRP + GHRH synergy principle first demonstrated with GHRP-1-class peptides remains the foundation of modern GH secretagogue combination research (Bowers, 1998).
Pharmacokinetic Profile
GHRP-1 — Pharmacokinetic Curve
Subcutaneous injection, IntravenousQuick Start
- Route
- Subcutaneous injection, Intravenous
Molecular Structure
- Formula
- C51H62N12O7
- Weight
- 955.1 Da
- CAS
- 142033-37-0
- PubChem CID
- 10350910
- Exact Mass
- 954.4864 Da
- LogP
- 2.8
- TPSA
- 314 Ų
- H-Bond Donors
- 11
- H-Bond Acceptors
- 10
- Rotatable Bonds
- 25
- Complexity
- 1750
Identifiers (SMILES, InChI)
InChI=1S/C51H62N12O7/c1-30(53)46(65)60-44(26-37-28-55-29-57-37)51(70)63-42(24-33-19-20-34-14-6-7-15-35(34)22-33)48(67)58-31(2)47(66)61-43(25-36-27-56-39-17-9-8-16-38(36)39)50(69)62-41(23-32-12-4-3-5-13-32)49(68)59-40(45(54)64)18-10-11-21-52/h3-9,12-17,19-20,22,27-31,40-44,56H,10-11,18,21,23-26,52-53H2,1-2H3,(H2,54,64)(H,55,57)(H,58,67)(H,59,68)(H,60,65)(H,61,66)(H,62,69)(H,63,70)/t30-,31-,40-,41+,42+,43-,44-/m0/s1
NWQWNCILOXTTHF-HLCSKTDOSA-NResearch Protocols
intravenous Injection
Bowers and colleagues administered GHRP-1 intravenously at doses ranging from 0.1 to 1.0 mcg/kg in healthy volunteers, measuring serial GH, cortisol, and prolactin levels at 15-minute intervals for 60-90 minutes post-injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 1.0 mcg | Per protocol | —(Route: Intravenous Injection) |
subcutaneous Injection
Administered via subcutaneous injection.
Interactions
Peptide Interactions
Like other GHRPs, GHRP-1 demonstrates synergistic GH release when co-administered with GHRH or its analogs. Because GHRPs and GHRH activate distinct receptor pathways on somatotroph cells, the combined stimulus produces GH pulses 3-10 times greater than either agent alone. This synergy was first ...
In practice, GHRP-2 or ipamorelin have replaced GHRP-1 in combination protocols due to superior potency and selectivity.
GHRP-1 is less commonly used in contemporary research compared to GHRP-2 and GHRP-6, which offer greater potency and better-characterized pharmacology.
GHRP-1 is less commonly used in contemporary research compared to GHRP-2 and GHRP-6, which offer greater potency and better-characterized pharmacology.
This work ultimately established an entirely new axis of GH regulation alongside GHRH and somatostatin.
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Red flags
- Significant side effect risk noted
Frequently Asked Questions
References (7)
- [7]
- [8]Muccioli et al -- Growth hormone-releasing peptides and the cardiovascular system Ann Endocrinol (2000)
- [1]Bowers CY *Cell Mol Life Sci* Cell Mol Life Sci (1998)
- [2]Bowers CY et al *Endocrinology* Endocrinology (1994)
- [3]Muccioli et al *Ann Endocrinol* Ann Endocrinol (2000)
- [5]Howard et al *Science* Science (1996)
- [6]Kojima et al *Nature* Nature (1999)
GHRH (Growth Hormone Releasing Hormone)
**Growth Hormone Releasing Hormone (GHRH)**, also known as Growth Hormone Releasing Factor (GRF) or Somatorelin, is a 44-amino acid peptide hormone produced by
GHRP-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin/growth hormone secretagogue receptor. It was the first gro